These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

820 related items for PubMed ID: 31703604

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K.
    Clin Cancer Res; 2018 Jun 01; 24(11):2653-2664. PubMed ID: 29530936
    [Abstract] [Full Text] [Related]

  • 4. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D, Jiang W, Zhu F, Mao X, Agrawal S.
    Int J Oncol; 2018 Sep 01; 53(3):1193-1203. PubMed ID: 29956749
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells.
    Song L, Bretz AC, Gravemeyer J, Spassova I, Muminova S, Gambichler T, Sriram A, Ferrone S, Becker JC.
    J Invest Dermatol; 2021 Apr 01; 141(4):903-912.e4. PubMed ID: 33002502
    [Abstract] [Full Text] [Related]

  • 7. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG.
    J Immunother Cancer; 2019 Feb 08; 7(1):37. PubMed ID: 30736857
    [Abstract] [Full Text] [Related]

  • 8. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
    Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG.
    Cancer Immunol Immunother; 2018 Mar 08; 67(3):381-392. PubMed ID: 29124315
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP, Mandl SJ, dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB.
    Cancer Immunol Immunother; 2016 May 08; 65(5):537-49. PubMed ID: 26961085
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy.
    Elia AR, Grioni M, Basso V, Curnis F, Freschi M, Corti A, Mondino A, Bellone M.
    Clin Cancer Res; 2018 May 01; 24(9):2171-2181. PubMed ID: 29490991
    [Abstract] [Full Text] [Related]

  • 15. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
    Roca MS, Moccia T, Iannelli F, Testa C, Vitagliano C, Minopoli M, Camerlingo R, De Riso G, De Cecio R, Bruzzese F, Conte M, Altucci L, Di Gennaro E, Avallone A, Leone A, Budillon A.
    J Exp Clin Cancer Res; 2022 Mar 03; 41(1):83. PubMed ID: 35241126
    [Abstract] [Full Text] [Related]

  • 16. The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
    Bissonnette RP, Cesario RM, Goodenow B, Shojaei F, Gillings M.
    BMC Cancer; 2021 Aug 30; 21(1):969. PubMed ID: 34461854
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
    Palakurthi S, Kuraguchi M, Zacharek SJ, Zudaire E, Huang W, Bonal DM, Liu J, Dhaneshwar A, DePeaux K, Gowaski MR, Bailey D, Regan SN, Ivanova E, Ferrante C, English JM, Khosla A, Beck AH, Rytlewski JA, Sanders C, Laquerre S, Bittinger MA, Kirschmeier PT, Packman K, Janne PA, Moy C, Wong KK, Verona RI, Lorenzi MV.
    Cancer Immunol Res; 2019 Sep 30; 7(9):1457-1471. PubMed ID: 31331945
    [Abstract] [Full Text] [Related]

  • 20. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S, Kim SA, Nam GH, Hong Y, Kim GB, Choi Y, Lee S, Cho Y, Kwon M, Jeong C, Kim S, Kim IS.
    J Immunother Cancer; 2021 Jan 30; 9(1):. PubMed ID: 33479026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.